---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124563"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:17:51.232438+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Neumora Q3 net loss $72.5M; cash $341.3M; Ph3 MDD data around end-2024

## Summary
- Cash and marketable securities $341.3M; operations funded into mid-2026.
- Q3 R&D expenses $60.6M (vs $41.6M YoY); net loss $72.5M (vs $53.0M).
- Phase 3 KOASTAL-1 navacaprant topline data expected around end of 2024.
- KOASTAL-2/3 topline data H1 2025; navacaprant Phase 2 bipolar depression data H2 2025.
- NMRA-511 Phase 1b AD agitation data H2 2025; M4 PAM IND submission expected H1 2025.

## SEC filing metadata
- accession: 0000950170-24-124563
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000095017024124563/0000950170-24-124563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000095017024124563/nmra-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124563
- JSON: https://secwatch.observer/filing/0000950170-24-124563.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.